Bristol-Myers Squibb Co news

   Watch this stock
Showing stories 1 - 10 of about 151   

Articles published

BMY 58.55 +4.39 (8.11%)
price chart
5 Things Bristol-Myers Squibb Co.'s Management Wants You to Know
Like most of its Big Pharma peers, Bristol-Myers Squibb is undergoing major changes due to the patent cliff. Per its latest earnings report , for instance, the company saw third-quarter revenue drop by 4% to $3.92 billion, year over year, mostly due to ...
Bristol-Myers Squibb Company (BMY) Leading In Pre-Market Activity  TheStreet.com
Bristol-Myers Squibb CEO Sells $2650000 in Stock (BMY)  WKRB News
Related articles »  
OliPass Announces a Worldwide Discovery Alliance with Bristol-Myers Squibb ...
SUWON, South Korea, Oct. 28, 2014 /CNW/ -- OliPass, a privately held biopharmaceutical company focused on developing antisense medicines based on peptide nucleic acid (PNA) technology, today announced a worldwide strategic alliance with ...
Bristol-Myers Squibb signs deal with Korean company OliPass
Privately-held Korean biopharmaceutical company OliPass has announced a worldwide strategic alliance with US drug major Bristol-Myers Squibb (NYSE: BMY) to discover and develop therapeutics against multiple targets using OliPass' technology platform ...
Watch List Highlights - Bristol-Myers Squibb Co (NYSE:BMY), Moody's ...
Bristol-Myers Squibb Co (NYSE:BMY) reported Q3 adjusted EPS of $0.45, three cents better than the analyst consensus on Capital IQ.
Morgan Stanley Believes Bristol-Myers Squibb Co. Could Move Significantly ...
In a report published Thursday, Morgan Stanley analyst David Risinger reiterated an Overweight rating and $60.00 price target on Bristol-Myers Squibb Co. (NYSE: BMY). In the report, Morgan Stanley noted, �We think BMY stock could move up 10�15% to ...
Bristol-Myers Squibb Presents Data from Multiple New Studies at IDWeek 2014 ...  Business Wire (press release)
Market Update: Bristol-Myers Squibb Company (NYSE:BMY) - Bristol-Myers ...  Jutia Group
Related articles »  
Drugmakers Roundup -Bristol-Myers Squibb Co (NYSE:BMY), Merck & Co., Inc ...
Bristol-Myers Squibb Company's (NYSE:BMY) Q3 2014 earnings of 45 cents per share is more than the Zacks Consensus Approximation by 4 cents.
Bristol-Myers Squibb Co's Third-Quarter Earnings Beat the Street  Motley Fool
Bristol-Myers Tops Estimates on Strong Drug Sales  Bloomberg
Related articles »  
Stocks to Watch: Bristol-Myers Squibb Company (NYSE:BMY), TriQuint ...
Bristol-Myers Squibb (NYSE:BMY) will release its Q3 2014 results on October 24th. We expect strong performance from its key drugs Eliquis and Yervoy.
Bristol-Myers Squibb Co (BMY) Issues FY14 Earnings Guidance
Bristol-Myers Squibb logo Bristol-Myers Squibb Co (NYSE:BMY) updated its FY14 earnings guidance on Friday. The company provided EPS guidance of $1.70-1.80 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.78, ...
Today's Premarket Earnings: Bristol-Myers Squibb Co, Colgate-Palmolive ...
Bristol-Myers Squibb Co (BMY ) reported third quarter earnings of $721 million, or 43 cents per share, up from $692 million, or 42 cents per share a year ago.
Bristol-Myers Squibb Strategy Could Boost Share Price (BMY)
In the past year, the share price of Bristol-Myers Squibb (NYSE:BMY) has risen less than 1 percent, well below both the DJIA and the NYSE Arca Pharmaceutical Index (NYSE:DRG), a market-capitalization index designed to represent a cross section of ...